

# AC Contract Manufacturing: Change Control for HPC(A) and MNC(A)

Amy E. Hines BSN, RN, CHTC - Be The Match BioTherapies

Jody McNaughton - NMDP / Be The Match

Katherine St. Martin, MS, RAC(US) – NMDP / Be The Match

# Disclosures

The following faculty and planning committee staff have no financial disclosures:

Name	Institution
Amy E. Hines	Be The Match BioTherapies
Jody McNaughton	NMDP / Be The Match
Katherine St. Martin	NMDP / Be The Match
Ruth Bakken	NMDP / Be The Match
Jami Chapman	NMDP / Be The Match
Bette Braem	NMDP / Be The Match


# Learning objectives

At the conclusion of this session, attendees will be able to:

- List the main components of the NMDP AC Change Control process
- State the rationale for why NMDP is initiating a Change Control process as part of AC qualification



# What is AC Contract Manufacturing Qualification?



Process for retroactively qualifying existing ACs and ensuring ACs continually meet FDA requirements for the manufacturing of HPC(A) and MNC(A)

# Initial Qualification Process



Supplier  
Questionnaire



Onsite  
Audit



Qualification  
Review




# AC Contract Manufacturing Status

FY	Supplier Questionnaire	Audit	Qualified
FY16	9	9	8/9
FY17	All centers	15	8/15




# Timeline

Complete qualifications  
by mid-2020




# Change Control = Planned Changes

- Change control is a well-known manufacturing concept that focuses on managing change to prevent **unintended consequences**
- Change Control is industry best practice:
  - ICH Q10: Pharmaceutical Quality System
- It's also a core GTP/GMP requirement:
  - 21 CFR 1271.160(a): Quality Program
  - 21 CFR 1271.225: Process changes
  - 21 CFR 211.22: Quality Control Unit





# NMDP Change Control Process



# NMDP Change Control Process

- Integrated - Electronic process flow that integrates with document management, incident management and other quality processes
- Visible – Participants can track changes through process
- Capture Assessments – Impact assessments built into process
- Provides flexibility to add appropriate assessor
- Decisions – Way to document decisions and add supporting communication within process
- Risk – Change types are defined by FDA based on potential impact on product SQUIPP and incorporated into electronic process
- Reports – Able to produce reports of changes in process, overdue, closed, etc.

# Survey Results Discussion



# NMDP AC Change Control Process



Evaluate potential risk to product or process



Discuss impacted areas



Notify NMDP through web-based form \*



Implement

## Apheresis Center Change Notification

Apheresis Center:

AC # and name

First Name:

Primary

Last Name:

Coordinator

Email:

pcoordinator@ac.org

# NEW

1. NMDP / Be The Match requires notification of changes made by your center in any of the following areas.
2. Use this form to provide details of the change being made.
3. Submit a separate form for each change.

Select the area you are making a change to::

Apheresis Machines

Replacement, addition, and / or removal of apheresis machines. Include the manufacturer and model of the machine(s) being replaced and of any new machine(s).

Description of Change:

Adding two new Spectra Optia apheresis machines.

Reason for the change:

Replacing apheresis machines that are no longer supported by manufacturer

Estimated Effective Date of Change:

12/1/2016



Submit Change Notification



# When do I need to submit it?

Changes to/notifications about:

- Apheresis machine(s)
- Final labeling method
- Accreditation status
- FDA notification
- Central line provider
- Recalls impacting SQuIPP

# Deviations = Unplanned Changes

- Core Business Deviations
  - Real time Notification: Call the AC/CC Liaison Team
  - Allows the Transplant Center to stay informed, make adjustments
- New Business Development Deviations
  - Real time Notification: Call the BTMB AC Liaison Team
  - Determination of whether to collect; no patient awaiting the product

# Complaints, CAPA = Quality Incidents

- A problem, nonconformance, event or deviation that has adversely affected or has the potential to adversely affect manufacturing of an HPC product, patient or donor safety, confidentiality or compliance with NMDP Standards

# References

- Contact Information:
  - [AC\\_Contract\\_Manufact@NMDP.org](mailto:AC_Contract_Manufact@NMDP.org)
- Change Notification Form:
  - <https://network.bethematchclinical.org/My-Account/Apheresis-Center-Change-Notification/>



# Evaluation Reminder

Please complete the Council Meeting 2017 evaluation in order to receive continuing education credits and to provide suggestions for future topics.

We appreciate your feedback!